Treatment
XBD173 clinical trials
We’re tracking 6 recruiting studies that include XBD173, each written for real people, not researchers, below.
Recruiting studies
- NCT07697183Enrolling by invitationPhase 1
PET scan study for pulmonary arterial hypertension
This study uses a special PET scan tracer (XBD173) to look at inflammation in the lungs of people with pulmonary arterial hypertension (PAH). It aims to understand the role of a protein called TSPO in PAH and may help guide future treatments.
LondonAges 18–75 - NCT07191821Enrolling by invitationPhase 2
TSPO modulation for Alzheimer's disease
This trial tests a drug that targets a brain protein called TSPO in people with mild to moderate Alzheimer's. It aims to see if this approach can slow memory loss.
LondonAges 18–90 - NCT03850301Recruiting
Testing a brain inflammation target using an investigational medicine
This study tests whether a medicine that targets a specific brain inflammation marker (TSPO) can help in people with certain types of multiple sclerosis. It focuses on safety and whether the target can be measured and influenced during treatment.
London, EnglandAges 35–65 - NCT06643013Recruiting
Targeting brain blood vessels to help small vessel disease
This study tests a drug that targets a protein called TSPO to see if it can improve the function of the cells lining the small blood vessels in the brain of people with cerebral small vessel disease. It may help with mild memory or thinking problems.
LondonAges 60–90 - NCT07682233RecruitingPhase 2
Study on a mitochondrial target and blood sugar control
This study tests a medicine called XBD173 to see how it affects blood sugar by targeting a protein inside cells' mitochondria. It may help people without diabetes learn about new ways to regulate blood sugar.
LondonAges 18–75 - NCT07362290Enrolling by invitation
Study of drug binding in the lungs using PET scan
This study uses a special PET scan to see how a drug (XBD173) binds to a protein in the lungs. It may help researchers understand inflammation in the lungs and find new ways to treat lung diseases.
LondonAges 25–75
What XBD173 is being studied for
Conditions with recruiting XBD173 studies.
Common questions
- Are there clinical trials studying XBD173?
- Yes. Clin2 currently lists 6 recruiting studies that include XBD173, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a XBD173 trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is XBD173 an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether XBD173 or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.